KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Capital Leases (2020 - 2022)

Ginkgo Bioworks Holdings' Capital Leases history spans 3 years, with the latest figure at $59.8 million for Q3 2022.

  • For Q3 2022, Capital Leases rose 267.85% year-over-year to $59.8 million; the TTM value through Sep 2022 reached $59.8 million, up 267.85%, while the annual FY2021 figure was $22.3 million, 34.9% up from the prior year.
  • Capital Leases reached $59.8 million in Q3 2022 per DNA's latest filing, up from $51.5 million in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $59.8 million in Q3 2022 to a low of $16.3 million in Q3 2021.
  • Average Capital Leases over 3 years is $32.3 million, with a median of $24.8 million recorded in 2021.
  • Peak YoY movement for Capital Leases: skyrocketed 34.9% in 2021, then surged 267.85% in 2022.
  • A 3-year view of Capital Leases shows it stood at $16.5 million in 2020, then skyrocketed by 34.9% to $22.3 million in 2021, then skyrocketed by 168.55% to $59.8 million in 2022.
  • Per Business Quant, the three most recent readings for DNA's Capital Leases are $59.8 million (Q3 2022), $51.5 million (Q2 2022), and $27.3 million (Q1 2022).